Experience with the use of sampeginterferon beta-1a in real clinical practice in the Moscow region

Abstract

The combination of polyethylene glycol with interferon beta-1a has expanded the therapeutic possibilities for treating multiple sclerosis (MS). By prolonging the half-life of interferon beta-1a and increasing its effect, this new formula provides safe and effective first-line therapy with reduced frequency of administration.

Objective: to investigate the safety and efficacy of intramuscular sampeginterferon beta-1a (SPI) in patients with relapsing-remitting MS, as well as factors influencing discontinuation of treatment.

Material and methods. Data from 14 patients with relapsing-remitting MS with mild activity who received SPI therapy at the Moscow Region Multiple Sclerosis Centre between June 2024 and May 2025 were analysed.

Results. During the year prior to the appointment of SPI, exacerbations of MS were observed in almost half (40%) of patients; during the period of SPI therapy (1 year), there were no exacerbations. The positive effect of SPI was confirmed by brain neuroimaging data and the absence of an increase in neurological deficit on the EDSS scale throughout the observation period. All recorded adverse reactions were of first or second degree severity and did not require discontinuation of SPI. A distinctive feature of SPI use was a significant reduction in the frequency of local reactions, which contributed to increased patient adherence to the therapy.

Conclusion. Preliminary analysis results demonstrate the efficacy and safety of SPI therapy in patients with relapsing-remitting MS. Infrequent injections of the drug contribute to increased patient adherence to pathogenetic treatment and improved quality of life.